EUVIMEDEUVIMED entdecken
Crossref

From Invisible to Enrolled: How Artificial Intelligence Is Reshaping Clinical Trial Recruitment

Sangzin Ahn

Pharmaceutical Medicine · 06.09.2026

DOI: 10.1007/s40290-026-00635-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Medicine, online erschienen am 06.09.2026. Verfasst von Sangzin Ahn. Beteiligte Einrichtung: Department of Pharmacology and Institute of Pharmacogenomics and Precision Medicine, Inje University College of Medicine, Busan, Korea. sangzinahn@in…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trial recruitment continues to fail at scale, with eligible patients often invisible to routine screening despite being present in electronic health records. Disease stage, treatment response, biomarker results, and clinical reasoning are frequently documented in narrative form rather than structured fields, placing eligibility-relevant information beyond the reach of conventional recruitment workflows. This narrative review examines applications of artificial intelligence (AI), and particularly large language models, across the recruitment pipeline. The evidence is organized around two ceilings. The discovery ceiling reflects the limits of identifying eligible candidates in clinical data, and current evidence suggests AI can raise it, improving discovery and screening efficiency in defined workflows. The enrollment ceiling reflects the human, logistical, ethical, and institutional barriers that persist after a patient has been identified. AI can make invisible patients visible, but visibility is not enrollment, and AI alone cannot remove these barriers. Upstream applications in trial design, predictive enrichment, site selection, and patient-facing engagement are also reviewed, together with governance requirements for equity, privacy, regulation, and workflow integration. Current evidence remains concentrated in retrospective evaluations, with limited prospective, multicenter validation and few demonstrated gains in enrollment, representativeness, or cost effectiveness. Recruitment AI is therefore best treated as a governed, human-supervised support tool that is locally validated and evaluated against downstream outcomes such as enrollment, diversity, burden, and cost.

Autor:innen und Institutionen

  • Department of Pharmacology and Institute of Pharmacogenomics and Precision Medicine, Inje University College of Medicine, Busan, Korea. sangzinahn@inje.ac.kr.
  • Cardiovascular and Metabolic Diseases Medical Research Center, Inje University College of Medicine, Busan, Korea. sangzinahn@inje.ac.kr.

Förderung

  • National Research Foundation of Korea (NRF)

Zitieren

APA

Ahn, S. (2026). From Invisible to Enrolled: How Artificial Intelligence Is Reshaping Clinical Trial Recruitment. Pharmaceutical Medicine. https://doi.org/10.1007/s40290-026-00635-9

Vancouver

Ahn S. From Invisible to Enrolled: How Artificial Intelligence Is Reshaping Clinical Trial Recruitment. Pharmaceutical Medicine. 2026. doi:10.1007/s40290-026-00635-9

BibTeX
@article{Ahn2026,
  author = {Ahn, Sangzin},
  title = {From Invisible to Enrolled: How Artificial Intelligence Is Reshaping Clinical Trial Recruitment},
  journal = {Pharmaceutical Medicine},
  year = {2026},
  doi = {10.1007/s40290-026-00635-9}
}
Kostenlos starten →